Feedback
Settings

Settings

Goto Application

142,347 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 14,235
1.20240247051METHODS OF IMMUNOTHERAPY
US - 25.07.2024
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No 18430151 Applicant Yigal Adir Inventor Yigal Adir

The disclosure features a method which includes isolating an infectious agent from a human patient infected with the infectious agent, obtaining one or more immunoproteins, immunopolypeptides, and immunopeptides from serum from a non-domesticated wild animal by inoculating, in vivo, the non-domesticated wild animal with the isolated infectious agent or inoculating, in vitro, blood taken from the non-domesticated wild animal with the isolated infectious agent, comparing a protein, polypeptide, and peptide composition of serum obtained from blood from the non-domesticated wild animal inoculated in vivo or serum obtained from in vitro inoculated blood from the non-domesticated wild animal to that of a serum sample obtained from blood from the non-domesticated wild animal prior to inoculation or from non-inoculated blood, to identify the one or more immunoproteins, immunopolypeptides, and immunopeptides, and isolating and purifying the one or more immunoproteins, immunopolypeptides, and immunopeptides, and administering them to the infected human patient.

2.20240245674DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
US - 25.07.2024
Int.Class A61K 31/473
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
 Appl.No 18561965 Applicant LINNAEUS THERAPEUTICS, INC. Inventor Christopher NATALE

The present disclosure provides diagnostic methods and compositions usefid in the identification of patients and cancers that are amenable to treatment with cancer therapies, including agonist therapies against cancer targets that exist in normal and cancerous cells and tissues.

3.20240245721DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS
US - 25.07.2024
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
 Appl.No 18558882 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor Kytai NGUYEN

Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.

4.20240245758IMMUNOMODULATION OF TUMOR MICROENVIRONMENT
US - 25.07.2024
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
 Appl.No 18563348 Applicant CLS THERAPEUTICS LIMITED Inventor Dmitry Dmitrievich GENKIN

The invention relates to methods for immunomodulation of immunosuppressive tumor cell microenvironment and prevention of tumor microbiome effects through multiple pathways with DNase enzyme therapy. Methods for immunomodulation of immunosuppressive tumor cell microenvironment comprising administering an effective amount of deoxyribonuclease (DNase) enzyme, either alone or in combination with other immunomodulating agent.

5.WO/2024/152112G PROTEIN-COUPLED RECEPTOR (GPCR) ANTIBODIES COUPLED TO HOMOLOGOUS DIMERIZATION (HD) PEPTIDES
WO - 25.07.2024
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CA2024/050046 Applicant MORGAN, Alton C. Inventor MORGAN, Alton C.
G protein-coupled receptor (GPCR) antibodies coupled to an HD peptide are disclosed, as well as methods of manufacture and uses of said antibodies. The HD peptides may comprise (i) an amino acid sequence of a naturally occurring HD peptide, or a conservative variant thereof, (ii) an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide, or a conservative variant thereof; (iii) an amino acid sequence of a naturally occurring HD peptide with one or more hydrophilic substitutions, or (iv) an HD peptide dimer.
6.WO/2024/155907EPITOPE-SCAFFOLD IMMUNOGENS FOR PANCORONAVIRUS VACCINES
WO - 25.07.2024
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2024/012189 Applicant DUKE UNIVERSITY Inventor AZOITEI, Mihai
Disclosed are immunogens for stimulating an immune response to coronaviruses. The immunogens can be non-receptor binding domain (RED) epitopes. The immunogens can be grafted into a scaffold polypeptide to produce an epitope scaffold. Antibodies induced by the immunogens are disclosed.
7.WO/2024/156012COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING INTO LIPID-BASED CARRIERS
WO - 25.07.2024
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
 Appl.No PCT/US2024/017222 Applicant UNIVERSITY OF NOTRE DAME DU LAC Inventor WANG, Yichun
Described herein are compositions and methods for enhanced drug loading into lipid-based carriers. The compositions and methods may comprise a drug-bound chiral graphene quantum dot comprising a graphene quantum dot functionalized with a non-aromatic chiral ligand having a single chiral center, wherein a chirality of the chiral graphene quantum dot matches a chirality of a lipid content of the lipid-based carrier. The drug-bound chiral graphene quantum dot permeates into the lipid-based carrier via matching of the chirality of the chiral graphene quantum dot to the chirality of the lipid content of the lipid-based carrier to load the drug into the lipid-based carrier. The compositions and methods achieve a drug loading efficiency of greater than 60% into lipid-based carriers.
8.20240247069FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF
US - 25.07.2024
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18412280 Applicant Regeneron Pharmaceuticals, Inc. Inventor Yan YANG

The present disclosure relates to molecules capable of binding to FGFR3 and methods of use thereof.

9.20240245779METHODS OF MODELING LIQUID PROTEIN COMPOSITION STABILITY
US - 25.07.2024
Int.Class A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
 Appl.No 18420955 Applicant Regeneron Pharmaceuticals, Inc. Inventor Douglas E. KAMEN

The disclosure provides methods of determining an initial amount of surfactant to include in a liquid pharmaceutical composition comprising a protein, intended for administration to a subject as an IV admixture. The methods comprise determining the degradation rate of the surfactant, the minimum amount of surfactant whereby stability of the protein is maintained in IV admixture the end of shelf-life of the liquid pharmaceutical composition, and, based on the degradation rate, shelf-life, and minimum amount of surfactant, determining a target amount of surfactant to include in the composition at the time of formulation.

10.20240245792HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB
US - 25.07.2024
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
 Appl.No 18525282 Applicant Synthorx, Inc. Inventor Giovanni Abbadessa

Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with one or more additional agents.

# -